Purpose Of The Study: Tetanus epidemiological assessment of the situation in Poland in 2011.
Materials And Methods: We used the data published in the annual bulletin "Infectious diseases and poisonings in Poland in 2011" and "Vaccinations in 2011" (NIPH-NIH-Department of Epidemiology, GIS - Department of Prevention and Control of Infectious Diseases in Humans - Warsaw 2012) and individual reports sent to the Department of Epidemiology NIPH-NIH RESULTS: In 2011 there were reported 14 cases of tetanus--(incidence 0.036/100 000) two less than in 2010. The patients were aged 50 years or more. Among them 4 persons were vaccinated. In remaining 10 cases there was a lack of data on vaccination. 5 patients died (35.7%).
Conclusions: The incidence of tetanus in Poland occurs mostly in people aged above 50 years of age. Vaccination should be promoted among the elderly in the recommended intervals, every 10 years.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Passive Immunisation in the Treatment of Infectious Diseases Related to Highly Potent Bacterial Toxins.
Biomedicines
December 2024
National Institute of Public Health NIH-National Research Institute, Chocimska 24, 00-791 Warsaw, Poland.
The discovery of microbial toxins as the primary factors responsible for disease manifestations and the discovery that these toxins could be neutralised by antitoxins are linked to the birth of immunology. In the late 19th century, the serum or plasma of animals or patients who had recovered from infectious diseases or who had been immunised with a relevant antigen began to be used to treat or prevent infections. Before the advent of widespread vaccination campaigns, antitoxins played a key role in the treatment and prevention of diseases such as diphtheria and tetanus.
View Article and Find Full Text PDFVaccination of pregnant women: an overview of European policies and strategies to promote it.
Front Public Health
December 2024
Department of Medicine and Surgery, University of Perugia, Perugia, Italy.
Maternal immunization is a valuable tool for protecting mother and unborn child from vaccine-preventable diseases. However, the implementation of strategies for vaccinating pregnant women has only recently gained traction. This work is aimed at providing an overview of European vaccination strategies and gathering evidence on interventions enhancing vaccination knowledge, attitudes, and behaviors (KAB) in pregnant women.
View Article and Find Full Text PDFSeroprevalence of IgG antibodies against tetanus toxoid among different age groups in Poland.
Ann Agric Environ Med
September 2024
National Institute of Public Health NIH - National Research Institute, Warsaw, Poland.
Article Synopsis
- The study aimed to assess the prevalence of tetanus antibodies in the population to gauge vaccine-induced immunity and identify groups needing booster shots.* -
- A total of 2,842 serum samples from individuals aged 1 month to 97 years were tested, revealing that 5.2% had low antibody levels and over half required immediate booster vaccinations.* -
- Results indicated that young adults showed the highest antibody levels and avidity, while older adults (70+) had significantly lower immunity, suggesting they are the main target for booster doses.*
Evaluation of the Development of Post-Vaccination Immunity against Selected Bacterial Diseases in Children of Post-Solid-Organ-Transplant Mothers.
Vaccines (Basel)
May 2024
Department of Neonatology and Rare Diseases, Faculty of Health Sciences, Medical University of Warsaw, 02-091 Warsaw, Poland.
Pregnancy after organ transplantation is considered high-risk and requires supervision in specialized centers. The impact of immunosuppression on the developing fetus is still the subject of research. It has been shown that it affects lymphocyte populations in the first year of life.
View Article and Find Full Text PDFPhase 3 Safety and Immunogenicity Study of a Three-dose Series of Twenty-valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers.
Pediatr Infect Dis J
June 2024
Vaccine Research and Development, Pfizer Inc, Collegeville, Pennsylvania.
Background: Global pediatric immunization programs with pneumococcal conjugate vaccines (PCVs) have reduced vaccine-type pneumococcal disease, but a substantial disease burden of non-PCV serotypes remains.
Methods: This phase 3, randomized (1:1), double-blind study evaluated safety and immunogenicity of 20-valent PCV (PCV20) relative to 13-valent PCV (PCV13) in healthy infants. Participants received 2 infant doses and a toddler dose of PCV20 or PCV13, with diphtheria-tetanus-acellular pertussis combination vaccine at all doses and measles, mumps, rubella and varicella vaccines at the toddler dose.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!